{"organizations": [], "uuid": "e5af0f67be019ea8ed1ecee6124ed3e4388224c2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180403.html", "section_title": "Archive News &amp; Video for Tuesday, 03 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-idt-australia-to-divest-selection/brief-idt-australia-to-divest-selection-of-generic-product-portfolio-to-ani-pharmaceuticals-idUSFWN1RG0UB", "country": "US", "domain_rank": 408, "title": "BRIEF-IDT Australia To Divest Selection Of Generic Product Portfolio To Ani Pharmaceuticals", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.041, "site_type": "news", "published": "2018-04-04T07:30:00.000+03:00", "replies_count": 0, "uuid": "e5af0f67be019ea8ed1ecee6124ed3e4388224c2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-idt-australia-to-divest-selection/brief-idt-australia-to-divest-selection-of-generic-product-portfolio-to-ani-pharmaceuticals-idUSFWN1RG0UB", "ord_in_thread": 0, "title": "BRIEF-IDT Australia To Divest Selection Of Generic Product Portfolio To Ani Pharmaceuticals", "locations": [], "entities": {"persons": [], "locations": [{"name": "australia", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "idt australia ltd", "sentiment": "negative"}, {"name": "pharmaceuticals inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 4 (Reuters) - IDT Australia Ltd:\n* TO DIVEST A SELECTION OF ITS GENERIC PRODUCT PORTFOLIO TO ANI PHARMACEUTICALS INC\n* ‍IDT WILL RECEIVE US$2.7 MILLION * ‍IDT WILL RETAIN A SHARE OF NET PROFIT FROM PRAZOSIN FUTURE SALES FOR 60 MONTHS​\n* WILL RETAIN RIGHT TO MANUFACTURE AND SUPPLY DOXAZOSIN MESYLATE AND CALCIUM LEUCOVORIN ON A CONTRACT MANUFACTURE FOR PROFIT BASIS​ Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-04T07:30:00.000+03:00", "crawled": "2018-04-04T12:33:20.021+03:00", "highlightTitle": ""}